Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.23|
|52 Week High||US$0.96|
|52 Week Low||US$5.00|
|1 Month Change||18.27%|
|3 Month Change||-12.77%|
|1 Year Change||-74.00%|
|3 Year Change||-60.95%|
|5 Year Change||-41.43%|
|Change since IPO||-89.52%|
Recent News & Updates
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Evoke Pharma announces positive findings from second GIMOTI market research study
Evoke Pharma (EVOK) announces positive findings from a second market research study conducted for GIMOTI (metoclopramide) nasal spray.The study aimed to gather further market insights on perception of GIMOTI in the GI community. In May 2021, Evoke’s commercialization partner, EVERSANA, conducted the GIMOTI Awareness, Trial, Usage ((ATU)) Study. The study objectives were to understand the current gastroparesis treatment landscape and to evaluate physicians’ perceptions of GIMOTI following recent brand marketing efforts. Key findings are as follows: Continued increase in intent to prescribe
Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Evoke Pharma (EVOK) jumps 8.4% premarket in reaction to the announcement that its US patent No. 11,020,361 for Gimoti (metoclopramide) nasal spray is now listed in the FDA's “Orange Book”.The patent covers methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis and carries a patent term to at least 2029. The FDA approved the NDA for Gimoti in June 2020.
Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Evoke Pharma (EVOK) announces that the United States Patent and Trademark Office ((USPTO)) has issued US patent no. 11,020,361 to the company related to Gimoti (metoclopramide) nasal spray. The patent covers methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.Shares up more than 2% premarket.
|EVOK||US Pharmaceuticals||US Market|
Return vs Industry: EVOK underperformed the US Pharmaceuticals industry which returned 13.3% over the past year.
Return vs Market: EVOK underperformed the US Market which returned 33% over the past year.
Stable Share Price: EVOK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: EVOK's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma Fundamentals Summary
|EVOK fundamental statistics|
Is EVOK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EVOK income statement (TTM)|
|Cost of Revenue||US$219.72k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.32|
|Net Profit Margin||-2,654.60%|
How did EVOK perform over the long term?See historical performance and comparison
Is Evoke Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EVOK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EVOK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EVOK is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: EVOK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EVOK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EVOK is overvalued based on its PB Ratio (6.7x) compared to the US Pharmaceuticals industry average (3.1x).
How is Evoke Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVOK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EVOK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EVOK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EVOK's revenue (102.3% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: EVOK's revenue (102.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EVOK's Return on Equity is forecast to be high in 3 years time
How has Evoke Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EVOK is currently unprofitable.
Growing Profit Margin: EVOK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EVOK is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare EVOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: EVOK has a negative Return on Equity (-155.78%), as it is currently unprofitable.
How is Evoke Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: EVOK's short term assets ($17.5M) exceed its short term liabilities ($6.2M).
Long Term Liabilities: EVOK's short term assets ($17.5M) exceed its long term liabilities ($5.4M).
Debt to Equity History and Analysis
Debt Level: EVOK's debt to equity ratio (83.8%) is considered high.
Reducing Debt: EVOK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVOK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EVOK has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 10% each year.
What is Evoke Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVOK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVOK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EVOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Gonyer (57 yo)
Mr. David A. Gonyer, also known as Dave, R.Ph., is a Co-Founder of Evoke Pharma, Inc. and has been its Chief Executive Officer and President since March 2007. Mr. Gonyer held senior management positions bo...
CEO Compensation Analysis
Compensation vs Market: Dave's total compensation ($USD1.17M) is above average for companies of similar size in the US market ($USD545.11K).
Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.
Experienced Management: EVOK's management team is seasoned and experienced (7.8 years average tenure).
Experienced Board: EVOK's board of directors are seasoned and experienced ( 14.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.7%.
Evoke Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: Evoke Pharma, Inc.
- Ticker: EVOK
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$39.900m
- Shares outstanding: 32.44m
- Website: https://www.evokepharma.com
Number of Employees
- Evoke Pharma, Inc.
- 420 Stevens Avenue
- Suite 370
- Solana Beach
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 00:19|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.